Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Axial spondyloarthritis classification criteria: the debate continues

Dubreuil, Maureena,b; Deodhar, Atul A.c

Current Opinion in Rheumatology: July 2017 - Volume 29 - Issue 4 - p 317–322
doi: 10.1097/BOR.0000000000000402

Purpose of review The Assessment of Spondyloarthritis International Society (ASAS) axial spondyloarthritis (axSpA) classification criteria marked a major step forward in SpA research, distinguishing axial from peripheral disease, and allowing earlier identification through MRI. This facilitated all aspects of research including epidemiology, therapeutics and patient outcomes.

Recent findings The ASAS axSpA classification criteria have been applied broadly in research, and were validated in a recent meta-analysis of international studies. Concerns arose because of clinical differences between the clinical and imaging arms, which imply different risk for radiographic progression, and perform differently in validation studies. Low specificity of the MRI finding of sacroiliac joint bone marrow edema may lead to misclassification in populations with low axSpA prevalence. We suggest methodology to improve upon the criteria, including rigorous assessment of potential candidate criteria sets, discrete choice experiments to allow consideration of feature weights, and validation. Separately, assessment of structural and inflammatory MRI abnormalities should be performed to refine the MRI definition of sacroiliitis.

Summary The debate regarding the validation and modification of the ASAS axSpA classification criteria should lead to international efforts to build upon the gains made by these criteria, to further refine the axSpA population definitions for research and ultimately improve patient outcomes.

aBoston University School of Medicine

bVA Boston Healthcare Center, Boston, Massachusetts

cOregon Health & Science University, Portland, Oregon

Correspondence to Atul A. Deodhar, MD, Division of Arthritis and Rheumatic Diseases (OP09), Oregon Health & Science University, Portland, OR 97239. Tel: +1 503 494 8963; fax: +1 503 494 1133; e-mail:

Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.